SYNPR

Summary

SYNPR (synaptoporin, HGNC:16507) is a protein-coding gene on chromosome 3p14.2, encoding Synaptoporin (Q8TBG9). Intrinsic membrane protein of small synaptic vesicles.

Predicted to be involved in modulation of chemical synaptic transmission. Predicted to be located in membrane; neuron projection; and synaptic vesicle. Predicted to be active in hippocampal mossy fiber to CA3 synapse and synaptic vesicle membrane.

Source: NCBI Gene 132204 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 45 total — 2 pathogenic
• MANE Select transcript: NM_001130003

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16507
Approved symbol	SYNPR
Name	synaptoporin
Location	3p14.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC26651, SPO
Ensembl gene	ENSG00000163630
Ensembl biotype	protein_coding
Entrez	132204

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 7 protein_coding, 6 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000295894, ENST00000450542, ENST00000460142, ENST00000460711, ENST00000465156, ENST00000467934, ENST00000468110, ENST00000472899, ENST00000478300, ENST00000478456, ENST00000478744, ENST00000479198, ENST00000493532, ENST00000496889, ENST00000498449

RefSeq mRNA: 2 — MANE Select: NM_001130003 NM_001130003, NM_144642

CCDS: CCDS46859, CCDS46860

Canonical transcript exons

ENST00000478300 — 6 exons

Exon	Start	End
ENSE00001769487	63278677	63278742
ENSE00001872950	63278308	63278551
ENSE00003554639	63556543	63556741
ENSE00003585776	63480832	63480956
ENSE00003620835	63609125	63609316
ENSE00003850115	63615224	63616924

Expression profiles

Bgee: expression breadth ubiquitous, 156 present calls, max score 99.03.

FANTOM5 (CAGE): breadth broad, TPM avg 6.6554 / max 992.1752, expressed in 230 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37120	2.6972	210
37130	2.3303	92
37131	0.5476	77
37127	0.2971	68
37126	0.2688	67
37123	0.1924	65
37128	0.1705	61
37124	0.0794	42
37129	0.0313	17
37125	0.0289	9

Top tissues by expression

239 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	99.03	gold quality
cerebellar vermis	UBERON:0004720	98.97	gold quality
nucleus accumbens	UBERON:0001882	98.32	gold quality
lateral globus pallidus	UBERON:0002476	98.31	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.08	gold quality
middle temporal gyrus	UBERON:0002771	97.93	gold quality
caudate nucleus	UBERON:0001873	96.96	gold quality
cerebellum	UBERON:0002037	96.74	gold quality
cerebellar cortex	UBERON:0002129	96.59	gold quality
cerebellar hemisphere	UBERON:0002245	96.53	gold quality
superior frontal gyrus	UBERON:0002661	96.50	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.46	gold quality
putamen	UBERON:0001874	96.02	gold quality
prefrontal cortex	UBERON:0000451	96.01	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.88	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.81	gold quality
postcentral gyrus	UBERON:0002581	95.68	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.36	gold quality
parietal lobe	UBERON:0001872	95.26	gold quality
frontal cortex	UBERON:0001870	94.73	gold quality
entorhinal cortex	UBERON:0002728	94.50	gold quality
anterior cingulate cortex	UBERON:0009835	94.40	gold quality
Ammon’s horn	UBERON:0001954	94.28	gold quality
cerebral cortex	UBERON:0000956	94.07	gold quality
neocortex	UBERON:0001950	93.72	gold quality
temporal lobe	UBERON:0001871	93.64	gold quality
amygdala	UBERON:0001876	92.78	gold quality
endothelial cell	CL:0000115	92.06	gold quality
occipital lobe	UBERON:0002021	91.73	gold quality
right frontal lobe	UBERON:0002810	91.61	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	1630.31
E-HCAD-35	yes	1517.25
E-MTAB-7316	yes	1349.06
E-MTAB-11268	yes	823.37
E-GEOD-135922	yes	22.68
E-GEOD-84465	yes	6.75
E-ANND-3	yes	5.05
E-HCAD-30	no	1073.52

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

75 targeting SYNPR, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-875-3P	99.63	69.47	2548

Literature-anchored findings (GeneRIF, showing 3)

• Tyrosine nitration of synaptophysin is related to Amyloid beta induced impairment of acetylcholine release. (PMID:12740598)
• cloning and characterization of the human cDNA that encodes the human homologue of synaptoporin (PMID:12974474)
• Results from genome-wide association studies identify synaptoporin gene as one of the three susceptibility loci candidate for congenital left-sided lesions. (PMID:25138779)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	synpra	ENSDARG00000037587
mus_musculus	Synpr	ENSMUSG00000056296
rattus_norvegicus	Synpr	ENSRNOG00000008203
caenorhabditis_elegans		WBGENE00004979

Paralogs (3): SYPL1 (ENSG00000008282), SYP (ENSG00000102003), SYPL2 (ENSG00000143028)

Protein

Protein identifiers

Synaptoporin — Q8TBG9 (reviewed: Q8TBG9)

All UniProt accessions (8): Q8TBG9, B3KVD8, C9J0A2, C9J976, F8WDB8, F8WDF9, F8WE43, F8WF23

UniProt curated annotations — full annotation on UniProt →

Function. Intrinsic membrane protein of small synaptic vesicles. Probable vesicular channel protein.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane. Synapse. Synaptosome.

Similarity. Belongs to the synaptophysin/synaptobrevin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TBG9-1	1	yes
Q8TBG9-2	2

RefSeq proteins (2): NP_001123475, NP_653243 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001285	Synaptophysin/porin	Family
IPR008253	Marvel	Domain

Pfam: PF01284

UniProt features (24 total): topological domain 5, repeat 5, transmembrane region 4, region of interest 2, compositionally biased region 2, glycosylation site 2, chain 1, domain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TBG9-F1	75.98	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 212

Glycosylation sites (2): 33, 38

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 100 (showing top): TTTGTAG_MIR520D, TAL1ALPHAE47_01, TCF4_Q5, WTGAAAT_UNKNOWN, TCF11_01, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, AACTTT_UNKNOWN, MAF_Q6, GOCC_NEURON_PROJECTION, IK3_01, OCT1_B, RIGGI_EWING_SARCOMA_PROGENITOR_UP, chr3p14

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): synaptic vesicle membrane (GO:0030672), neuron projection (GO:0043005), synaptic vesicle (GO:0008021), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
synaptic vesicle	1
exocytic vesicle membrane	1
plasma membrane bounded cell projection	1
exocytic vesicle	1
presynapse	1
cellular anatomical structure	1
cytoplasm	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

2112 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SYNPR	SYNGR1	O43759	917
SYNPR	SYNGR2	O43760	734
SYNPR	SYN1	P17600	651
SYNPR	SV2B	Q7L1I2	558
SYNPR	RAB3A	P20336	549
SYNPR	ALS2	Q96Q42	540
SYNPR	SYNGR3	O43761	474
SYNPR	SLC17A7	Q9P2U7	461
SYNPR	SYT1	P21579	457
SYNPR	REELD1	A0A1B0GV85	448
SYNPR	BDNF	P23560	443
SYNPR	SYN2	Q92777	430
SYNPR	LRRTM1	Q86UE6	415
SYNPR	SYT6	Q5T7P8	406
SYNPR	FARP2	O94887	402
SYNPR	PICK1	Q9NRD5	402

IntAct

35 interactions, top by confidence:

A	B	Type	Score
SYNPR	FATE1	psi-mi:“MI:0915”(physical association)	0.560
FATE1	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
SYNPR	SMCO4	psi-mi:“MI:0915”(physical association)	0.560
SYNPR	DOLK	psi-mi:“MI:0915”(physical association)	0.560
PLPP6	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
TUSC5	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
KTN1	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
GALNT15	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
SLC1A1	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
GPR37L1	SYNPR	psi-mi:“MI:0915”(physical association)	0.560
SYNPR	ARLN	psi-mi:“MI:0915”(physical association)	0.560
SYNPR	LNPK	psi-mi:“MI:0915”(physical association)	0.500
SYNPR	LNPK	psi-mi:“MI:0915”(physical association)	0.400
SYNPR	CREB3	psi-mi:“MI:0915”(physical association)	0.370
SYNPR	SPAG9	psi-mi:“MI:0914”(association)	0.350
SMCO4	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
DOLK	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
PLPP6	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
TUSC5	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
KTN1	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
GALNT15	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
SLC1A1	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
GPR37L1	SYNPR	psi-mi:“MI:0915”(physical association)	0.000
ARLN	SYNPR	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (18): SYNPR (Two-hybrid), KIAA1715 (Affinity Capture-MS), KIAA1715 (Affinity Capture-MS), FATE1 (Two-hybrid), CREB3 (Two-hybrid), SYNPR (Two-hybrid), SYNPR (Two-hybrid), SYNPR (Two-hybrid), C4orf3 (Two-hybrid), SMCO4 (Two-hybrid), GPR37L1 (Two-hybrid), DOLK (Two-hybrid), TUSC5 (Two-hybrid), PPAPDC2 (Two-hybrid), KIAA1715 (Affinity Capture-MS)

ESM2 similar proteins: A2VE58, A3KQ86, A6H7B0, A7E3W5, A8MWL6, B2RZ87, O43759, O43760, O43761, O54980, O55100, O55101, O76735, O95473, P07825, P08247, P0DI73, P20488, P22831, P47987, P79826, Q08AU7, Q08DL4, Q28793, Q2YDD6, Q5EBF8, Q5R703, Q5RER2, Q5XGR0, Q5XIT3, Q5YJC1, Q62277, Q62876, Q642A2, Q6RW13, Q7JYV2, Q7TQJ1, Q8BGN8, Q8R191, Q8TBG9

Diamond homologs: O09117, O62646, O89104, P07825, P08247, P20488, P22831, Q16563, Q5VXT5, Q5YJC1, Q62277, Q8BGN8, Q8TBG9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	38
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
150755	GRCh38/hg38 3p14.3-14.1(chr3:57430538-64884522)x1	Pathogenic
814449	GRCh37/hg19 3p14.2-14.1(chr3:60449667-65561638)x1	Pathogenic

SpliceAI

2998 predictions. Top by Δscore:

Variant	Effect	Δscore
3:63278547:GTCAG:G	donor_gain	1.0000
3:63278550:AG:A	donor_loss	1.0000
3:63278551:GGTGA:G	donor_loss	1.0000
3:63278552:G:GA	donor_loss	1.0000
3:63288353:TTTAA:T	donor_gain	1.0000
3:63480830:A:AG	acceptor_gain	1.0000
3:63480831:G:GG	acceptor_gain	1.0000
3:63480952:TTCAG:T	donor_loss	1.0000
3:63480953:TCAGG:T	donor_loss	1.0000
3:63480954:CAGG:C	donor_loss	1.0000
3:63480955:AGG:A	donor_loss	1.0000
3:63480956:GGT:G	donor_loss	1.0000
3:63480957:G:T	donor_loss	1.0000
3:63480958:T:A	donor_loss	1.0000
3:63556737:TCATT:T	donor_gain	1.0000
3:63556739:ATT:A	donor_gain	1.0000
3:63556740:TT:T	donor_gain	1.0000
3:63556742:G:GG	donor_gain	1.0000
3:63609158:T:TA	acceptor_gain	1.0000
3:63278659:C:A	acceptor_gain	0.9900
3:63278665:A:AG	acceptor_gain	0.9900
3:63278666:T:G	acceptor_gain	0.9900
3:63278674:A:G	acceptor_gain	0.9900
3:63480826:CCACA:C	acceptor_loss	0.9900
3:63480827:CACAG:C	acceptor_loss	0.9900
3:63480828:ACAG:A	acceptor_loss	0.9900
3:63480829:C:G	acceptor_gain	0.9900
3:63480829:CAG:C	acceptor_loss	0.9900
3:63480830:A:C	acceptor_loss	0.9900
3:63480831:G:GA	acceptor_loss	0.9900

AlphaMissense

1857 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:63480850:T:C	F15L	1.000
3:63480852:T:A	F15L	1.000
3:63480852:T:G	F15L	1.000
3:63480952:T:C	F49L	1.000
3:63480954:C:A	F49L	1.000
3:63480954:C:G	F49L	1.000
3:63609158:T:A	W128R	1.000
3:63609158:T:C	W128R	1.000
3:63609179:T:A	W135R	1.000
3:63609179:T:C	W135R	1.000
3:63609181:G:C	W135C	1.000
3:63609181:G:T	W135C	1.000
3:63609192:T:C	L139P	1.000
3:63609312:C:T	S179F	1.000
3:63615230:G:A	G183R	1.000
3:63615230:G:C	G183R	1.000
3:63615231:G:A	G183E	1.000
3:63615241:C:A	N186K	1.000
3:63615241:C:G	N186K	1.000
3:63615251:T:A	W190R	1.000
3:63615251:T:C	W190R	1.000
3:63615269:T:C	F196L	1.000
3:63615271:T:A	F196L	1.000
3:63615271:T:G	F196L	1.000
3:63615280:G:C	K199N	1.000
3:63615280:G:T	K199N	1.000
3:63480848:C:A	A14E	0.999
3:63480860:G:A	C18Y	0.999
3:63480861:C:G	C18W	0.999
3:63480898:T:A	C31S	0.999

dbSNP variants (sampled 300 via entrez): RS1000006486 (3:63263529 T>C), RS1000007625 (3:63587975 A>G), RS1000011324 (3:63380948 A>C), RS1000013173 (3:63198674 T>C,G), RS1000020356 (3:63367571 G>A,C), RS1000031477 (3:63367944 T>C), RS1000034307 (3:63404549 G>A,T), RS1000035545 (3:63417454 C>T), RS1000036588 (3:63308363 T>C), RS1000042281 (3:63265800 C>T), RS1000048894 (3:63546137 G>C), RS1000050858 (3:63548384 G>A,C,T), RS1000055836 (3:63424170 T>C), RS1000061394 (3:63443073 G>A,T), RS1000069527 (3:63301738 T>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002572_2	Congenital left-sided heart lesions	3.000000e-07
GCST004718_10	Congenital heart disease (inherited effect)	4.000000e-06
GCST005231_46	Major depressive disorder	6.000000e-06
GCST008153_50	Lean body mass	9.000000e-06
GCST010172_13	Idiopathic downbeat nystagmus	9.000000e-06
GCST012498_3	Autism	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004995	lean body mass

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
mercuric bromide	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
methylmercuric chloride	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Lead	affects expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1
Aflatoxin B1	increases methylation	1
p-Chloromercuribenzoic Acid	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders